{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T15:14:59Z","timestamp":1769181299853,"version":"3.49.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioinform."],"abstract":"<jats:p>Variations in drug-metabolizing enzymes and transporters are associated with adverse drug reactions (ADRs). ADRs to cancer drugs can differ among populations owing to environmental and genetic differences. Due to limited resources and prohibitive costs associated with drug development, African countries rely on cancer drugs developed from non-African genetic backgrounds. Black Africans carry a high burden of ADRs partly because of the use of poorly optimized drugs. Black Africans are the least studied population despite being the most genetically diverse. There is a profound lack of pharmacogenetic studies in Black African populations, necessitating an urgent need for pharmacogenomic studies in Black African populations to optimize dosing and minimize ADRs. Using two common generic cancer drugs, capecitabine and cyclophosphamide, we leveraged the PharmGKB platform and several genomic databases to highlight the need for pharmacogenomic studies in Africa. Our computational approach identifies previously reported and unreported toxicity- and efficacy-associated variants that are overrepresented or underrepresented in Black Africans relative to other ethnicities. These findings suggest that capecitabine and cyclophosphamide may not work optimally and\/or may predispose Black Africans to ADRs. This underscores the need for population-based drug screening and development to minimize ADRs and guarantee better treatment outcomes. Since Black Africans are currently underrepresented in genomic studies, African scientists could adopt our low-cost approach to evaluate the suitability of existing drugs for treating diseases. However, in the long term, African scientists must initiate large-scale genomic studies that will drive the discovery of African-tailored drugs and promote the implementation of precision medicine on the continent.<\/jats:p>","DOI":"10.3389\/fbinf.2025.1555637","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T05:34:51Z","timestamp":1755149691000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Precision medicine on a budget in Africa: using existing genetic data to mitigate adverse drug reactions to conventional cancer drugs"],"prefix":"10.3389","volume":"5","author":[{"given":"Alexandra Lindsey","family":"Djomkam Zune","sequence":"first","affiliation":[]},{"given":"Charles Ochieng\u2019","family":"Olwal","sequence":"additional","affiliation":[]},{"given":"Emmanuel","family":"Agbeli","sequence":"additional","affiliation":[]},{"given":"Abdoulaye Banir\u00e9","family":"Diallo","sequence":"additional","affiliation":[]},{"given":"Emmanuella","family":"Amoako","sequence":"additional","affiliation":[]},{"given":"Yaw","family":"Bediako","sequence":"additional","affiliation":[]},{"given":"Lily","family":"Paemka","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"595219","DOI":"10.3389\/fphar.2020.595219","article-title":"Pharmacogenetics guidelines: overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines","volume":"11","author":"Abdullah-Koolmees","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3389\/fphar.2020.00406","article-title":"Population pharmacokinetic, pharmacogenetic, and pharmacodynamic analysis of cyclophosphamide in Ethiopian breast cancer patients","volume":"11","author":"Ahmed","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40615-015-0101-3","article-title":"Racial and ethnic disparities in adverse drug events: a systematic review of the literature","volume":"2","author":"Baehr","year":"2015","journal-title":"J. Racial Ethn. Health Disparities"},{"key":"B4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10552-024-01922-z","article-title":"Lymphoma in Sub-Saharan Africa: a scoping review of the epidemiology, treatment challenges, and patient pathways","volume":"36","author":"Baissa","year":"2025","journal-title":"Cancer Causes Control"},{"key":"B5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40264-015-0281-0","article-title":"Epidemiology of adverse drug reactions in Europe: a review of recent observational studies","volume":"38","author":"Bouvy","year":"2015","journal-title":"Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.20524\/aog.2022.0688","article-title":"Racial and ethnic differences in capecitabine toxicity in patients with gastrointestinal tract cancers","volume":"35","author":"Brazelton","year":"2022","journal-title":"Ann. Gastroenterol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/bmb\/ldx035","article-title":"Pharmacogenetics: a general review on progress to date","volume":"124","author":"Daly","year":"2017","journal-title":"Br. Med. Bull."},{"key":"B8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41397-019-0098-9","article-title":"Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review","volume":"20","author":"Eektimmerman","year":"2020","journal-title":"Pharmacogenomics J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.18632\/oncotarget.3289","article-title":"Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer","volume":"6","author":"Garc\u00eda-Gonz\u00e1lez","year":"2015","journal-title":"Oncotarget"},{"key":"B10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3389\/fphar.2018.00350","article-title":"Adverse drug reactions in hospitalized patients: results of the FORWARD (facilitation of reporting in hospital ward) study","volume":"9","author":"Giardina","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jcpo.2017.11.005","article-title":"Access to colorectal cancer (CRC) chemotherapy and the associated costs in a South African public healthcare patient cohort","volume":"15","author":"Herbst","year":"2018","journal-title":"J. Cancer Policy"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.18103\/mra.v10i9.2986","article-title":"The apportionment of pharmacogenomic variation: race, ethnicity, and adverse drug reactions","volume":"10","author":"Jordan","year":"2022","journal-title":"Med. Res. Arch."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/phar.1982","article-title":"Warfarin pharmacogenomics in diverse populations","volume":"37","author":"Kaye","year":"2017","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/oncolo\/oyac143","article-title":"Access to and affordability of World Health Organization essential medicines for cancer in Sub-Saharan Africa: examples from Kenya, Rwanda, and Uganda","volume":"27","author":"Kizub","year":"2022","journal-title":"Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2174\/187152010794474019","article-title":"Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents","volume":"10","author":"Lee","year":"2010","journal-title":"Anticancer Agents Med. Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1136\/bmj.38803.528113.55","article-title":"Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine","volume":"332","author":"McDowell","year":"2006","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","first-page":"651720","DOI":"10.3389\/fphar.2021.651720","article-title":"Role of pharmacogenetics in adverse drug reactions: an update towards personalized medicine","volume":"12","author":"Micaglio","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/ajp.0b013e3181bed0e3","article-title":"Self-efficacy for coping with cancer in a multiethnic sample of breast cancer patients: associations with barriers to pain management and distress","volume":"26","author":"Mosher","year":"2010","journal-title":"Clin. J. Pain"},{"key":"B19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.phrs.2017.03.021","article-title":"Identification of new SNPs associated with severe toxicity to capecitabine","volume":"120","author":"Pellicer","year":"2017","journal-title":"Pharmacol. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10549-016-3965-y","article-title":"Understanding racial differences in health-related quality of life in a population-based cohort of breast cancer survivors","volume":"159","author":"Pinheiro","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"B21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2217\/pme-2019-0110","article-title":"A review of clinical pharmacogenetics studies in African populations","volume":"17","author":"Radouani","year":"2020","journal-title":"Pers. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ebiom.2017.02.017","article-title":"African genetic diversity: implications for cytochrome P450-mediated drug metabolism and drug development","volume":"17","author":"Rajman","year":"2017","journal-title":"EBioMedicine"},{"key":"B23","first-page":"1","article-title":"Impact of genetic ancestry on outcomes in ECOG-ACRIN-5103","volume-title":"JCO Precis. Oncols","author":"Schneider","year":"2017"},{"key":"B24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/s1471-4914(01)01986-4","article-title":"Clinical application of pharmacogenetics","volume":"7","author":"Spear","year":"2001","journal-title":"Trends Mol. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3390\/genes11111295","article-title":"A review of the important role of CYP2D6 in pharmacogenomics","volume":"11","author":"Taylor","year":"2020","journal-title":"Genes"},{"key":"B26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/cpt.602","article-title":"Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium","volume":"101","author":"van der Wouden","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ijrobp.2014.06.042","article-title":"Racial variations in radiation-induced skin toxicity severity: data from a prospective cohort receiving postmastectomy radiation","volume":"90","author":"Wright","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/tpj.2013.32","article-title":"Germline genetic variants in ABCB1, ABCC1, and ALDH1A1 and risk of hematological and gastrointestinal toxicities in a SWOG phase III trial S0221 for breast cancer","volume":"14","author":"Yao","year":"2014","journal-title":"Pharmacogenomics J."}],"container-title":["Frontiers in Bioinformatics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbinf.2025.1555637\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T05:34:52Z","timestamp":1755149692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbinf.2025.1555637\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":28,"alternative-id":["10.3389\/fbinf.2025.1555637"],"URL":"https:\/\/doi.org\/10.3389\/fbinf.2025.1555637","relation":{},"ISSN":["2673-7647"],"issn-type":[{"value":"2673-7647","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"article-number":"1555637"}}